US FDA issued Letter Lundbeck Seattle Biopharmaceuticals alleging promotional materials migraine treatment Vyepti eptinezumab-jjmr contained false misleading claims overstated benefits.
FDA Vyepti Letter – Details
- Drug: Vyepti eptinezumab-jjmr intravenous monoclonal antibody approved preventive treatment migraine adults | Company: Lundbeck Seattle Biopharmaceuticals | Issue: Promotional materials HCP website
- Claims Flagged: Patients could achieve 100% migraine freedom month or more long-term improvements migraine severity disability productivity daily functioning brain fog
- FDA Finding: Claims relied heavily post-hoc analyses open-label studies observational research not sufficient evidence support definitive promotional statements no control groups exploratory analyses without prespecified statistical controls biases patient-reported outcomes misleading impression benefits conclusively demonstrated
- Action: Promotional webpages misbrand Vyepti under Federal Food Drug Cosmetic Act requested immediately stop or correct misleading communications written response within 15 working days corrective actions identifying similar materials in use
- Regulatory Note: Promotional claims prescription medicines must be supported substantial evidence accurately reflect approved labeling clinical data
Tags: FDA Letter Lundbeck Seattle Vyepti Eptinezumab Migraine False Misleading Claims 100% Migraine Freedom Brain Fog Disability Productivity, Post-Hoc Open-Label Observational Misbranding FD&C Act 15 Days Corrective Action IV Monoclonal Antibody Preventive
